Phaseline

Targets › KATG

KATG: drug programs, companies and trials

2 programs from 2 companies in 3 trials: 2 Phase 1, 1 Phase 2; Infectious disease; next expected readout Apr 2028.

Open in Phaseline: the race on KATG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Institute of Allergy and Infectious Diseases (NIAID)Isoniazid
Enoyl-[acyl-carrier-protein] reductase inhibitor
KATG, INHAPhase 2Tuberculous Meningitis; TuberculosisApr 2028
University Medical Center GroningenIsoniazid
Enoyl-[acyl-carrier-protein] reductase inhibitor
KATGPhase 1Tuberculosis–

Conditions

Tuberculosis (2) Tuberculous Meningitis (1)

Modalities

small molecule (2)

Companies

University Medical Center Groningen (1) National Institute of Allergy and Infectious Diseases (NIAID) (1)

Related targets

INHA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.